Navigation Links
Insights into Acute Promyelocytic Leukemia

The research, published in the July issue of the journal Cancer Cell, published by Cell Press , illuminates specific mechanisms involved in development of acute promyelocytic leukemia (APL) and identifies promising new avenues to develop treatments for some of its variant forms.

Results from two new studies provide key mechanistic insights into the complex molecular events that cause a deadly type of leukemia. APL is a cancer of the bone marrow that occurs when certain developing white blood cells get stuck at a highly proliferative and immature stage. The abnormal cells accumulate and eventually crowd out the normal, healthy blood cells.

Most cases of APL are caused by the expression of the PML/RARA (promyelocytic leukemia/retinoic acid receptor alpha) oncogene. This oncogene is formed by an abnormal translocation between two chromosomes and gives rise to a protein called a fusion protein.

In APL, the fusion protein, always involving the transcription factor RARA, acts as a potent transcriptional repressor that interferes with gene expression and prevents normal differentiation of white blood cells. Previous work of these two groups suggested that PML/RARA self-association, called homodimerization, and posttranslational modifications are important for transformation.

In addition, retinoid X receptor (RXR) has been shown to be present in the DNA-bound PML/RARA oncogenic complex and is thought to play a role in the ability of the fusion protein to bind to DNA and regulate gene expression.

Dr. Chi Wai Eric So from The Institute of Cancer Research in London and Dr. Shuo Dong from Baylor College of Medicine in Houston and their colleagues characterized the transformation mechanisms involved in APL by functionally separating homodimerization and the intrinsic DNA-binding properties of RARA fusions from transformation of primary blood cells.

The researchers found that homodimerization was
'"/>




Page: 1 2 3

Related medicine news :

1. Study Offers Insights Into Treatment Of Rheumatoid Arthritis
2. Reindeer Provide Valuable Insights Into Sleep Disorders
3. Insights Into Lead Pollution
4. Insights into Osteosarcoma in Cats and Dogs may Improve Palliative Care
5. New Insights into Antimalarial Drug Resistance
6. Neural Basis of Anxiety: Newer Insights
7. New Insights into Chronic Inflammation and Atherosclerosis
8. Rare Womens Lung Disease May Yield Insights Into Common Diseases
9. Neurotransmitter That can Yield New Insights in the Fight Against Diabetes Identified
10. Deep Insights into Type2 Diabetes by Wesley Researchers
11. New Insights into Prion Propogation

Post Your Comments:
(Date:12/2/2009)..., , ATLANTA, Dec. 2 In res...he U.S. military, FamilyLife, a non-profit ministr...will present its Weekend to Remember® marri...ry couples in Atlanta from Dec. 11 - 13 at the Gra...NE). Weekend to Remember is a marriage getaway ...
(Date:12/2/2009)..., , Ad in Today,s Washington Post H...swire-USNewswire/ -- If the Catholic bishops ha...tive measures we take for granted may be under thr...t to bear on the debate over healthcare reform has...shington Post warns of the likely impact if that ...
(Date:12/2/2009)..., , KANSAS CITY, Mo., Dec. 2 /PRN...mployers with a comprehensive, practical view on p...Congress. ,, (Logo: http://www.newscom.com/c...yers, there is good, bad, and ugly in the legislat...ttorneys in Lockton Benefit Group,s Compliance Se...
(Date:12/2/2009)...tudy finds myriad microbes in tobacco, but risk is...y News) -- New research provides evidence that th...ing bacteria that cause respiratory disease. , ... out, the authors of the new study aren,t sure wha...bacteria is nothing new: Microbes surround us ever...
(Date:12/2/2009)... Durham, NCDecember 2, 2009Ninety-six percent of l...dy on gender-based distrust indicated a strong gen...ver, this general distrust towards men did not pre...or romantic relationship. Furthermore, the union w...trusting," despite their prior assertions of distr...
Breaking Medicine News(10 mins):Health News:FamilyLife Supports Military Marriages in Atlanta 2Health News:Everybody's Healthcare Is Threatened by Catholic Bishops' Interference 2Health News:Lockton Outlines Implications of Proposed Health Reform Plans 2Health News:Smokers Inhaling Germs With Each Cigarette 2
... cancer cells are able to spread to distant parts ...ells spread to the target site via the blood or th...re. It has now emerged that certain chemicals ...rs from the Cornell University's Weill Medical Col...
... speech can be processed much faster by the brain ...cochlear implant is carried out at an early age//,...ts. About 36 profoundly deaf children aged between...at seeing to what extent children with the implant...
...ducted to determine the effectiveness of 27 differ...evels; sunflower seeds and pistachio nuts have bee... of high levels of phytosterol (plant chemicals wh...tion. On analysis, sesame seeds and wheat ge...
...m passive bystanders to good Samaritans in situati...ers report//. Occasions when a crowd of people...l known. Psychologists call it the "bystander effe... can become knights in shining armour. An exp...
...om color blindness due to X-chromosome variations,...olors but have an increased sensitivity to differe... be differentiated by normal persons. The results ...olors are differentiated by the eyes by cone photo...
...University of Birmingham tested the 'Bambach Saddl..., and have concluded that it serves to relieve bac...ds, was found to keep the spine in its natural 'S'... given a task to perform. This was based on the po...
Other Medicine News:Health News:Initial Steps In Spread Of Cancer Identified 2Health News:Early Cochlear Implants Prove To Be Effective 2Health News:Colorblind Individuals have expanded color vision 2Health News:New Chair Invented To Relieve Backache 2
(Date:12/2/2009)...LAGE, Nev., Dec. 2 PDL B...ced that it has established the per share amount o...vidend as $1.67 per share. The dividend will be pa...any,s stock as of the December 1, 2009 record date...per share amount of the dividend at $1.67 per shar...
(Date:12/2/2009)...EJO, Calif., Dec. 2 Clar...and services resource for pathologists, oncologist... a Chief Financial Officer transition plan that ca...riguez to become its Senior Vice President and Chi...J. Land, age 64, the current Senior Vice President...
(Date:12/2/2009)...ST HANOVER, N.J., Dec. 2 Novartis ...eaking presentation on Tasigna® (nilotinib) 2...ia, demonstrate the strength of the company,s hema.... ,, The new data, at the 51st American Societ...n, highlight the company,s current therapies and i...
Breaking Medicine Technology:PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 2PDL BioPharma Announces December 15 Special Dividend Payment of $1.67 per Share 3Clarient Announces CFO Transition Plan 2Clarient Announces CFO Transition Plan 3Clarient Announces CFO Transition Plan 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 2Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 3Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 4Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 5Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 6Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 7Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 8Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 9Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 10Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 11Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 12Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 13Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 14Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 15Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 16Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 17Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 18Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 19Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 20Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 21Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 22Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 23Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 24Significant potential of late- and mid-stage Novartis hematology portfolio to be showcased at upcoming ASH meeting 25Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 1Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 2Pandesa ShareVault Enables Secure Real time Due Diligence for Biopharmaceutical Partnering 14096 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 1Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 2Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 3Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 4Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 5Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 6Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 7Amgen to Present Pivotal Data From Four Phase 3 Studies at the ECCO 15 ESMO 34 Congress 57358 8Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 1Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 2Guayaki Delivers Powerful Rainforest Experience with Newest Yerba Mate Beverage Innovations 57354 3
...2/Insulin Significantly Lowered Blood Glucose with...ions,Phase 2 Trial Expected to Begin upon Ethics A... 2008, MELBOURNE, Australia, Aug. 8 ..., AIM: PSG, OTCQX: PPGNY) today,announced the succ...n,trial. The positive results of the trial demonst...
... Continued Investment in Clinical Development of T...uticals, Inc. (Nasdaq: TPPH ) announced today fin...7, 2007. The net loss for the second quarter of 2...pares to a net loss for the second quarter of 2006...the net loss for the second,quarter of 2007 and 20...
Other Medicine Technology:Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 2Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results 3Tapestry Reports Second Quarter 2007 Results 2Tapestry Reports Second Quarter 2007 Results 3Tapestry Reports Second Quarter 2007 Results 4Tapestry Reports Second Quarter 2007 Results 5Tapestry Reports Second Quarter 2007 Results 6
OneTouch® UltraSoft® Lancets
OneTouch® Fine Point™ Lancets
Microtainer Quikheel Lancet
HEMOCHRON Jr. Signature+ Microcoagulation System
Medicine Products: